Merck reported strong revenue growth in key segments like Oncology and Vaccines, and raised its 2023 guidance, which are positive signals. However, the one-time acquisition-related charges resulting in an EPS loss may exert short-term downward pressure on the stock. Overall, the balanced mix of positive performance and short-term financial headwinds suggests a slight negative impact in the near term.

[-1]